glucose, (beta-d)-isomer has been researched along with lansoprazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W; Liu, ZD; Pan, WS; Peng, B; Yang, XG; Zhang, GH | 1 |
| Abd El Fattah, MA; Ahmed, MAE; Eid, NI; Gamal El Din, AA; Gamil, NM; Maklad, YA | 1 |
2 other study(ies) available for glucose, (beta-d)-isomer and lansoprazole
| Article | Year |
|---|---|
Design and evaluation of jingzhiguanxin monolithic osmotic pump tablet.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzoates; Bridged-Ring Compounds; Delayed-Action Preparations; Drug Design; Drugs, Chinese Herbal; Glucosides; Lactates; Lansoprazole; Monoterpenes; Omeprazole; Osmosis; Polyethylene Glycols; Solubility; Spectrophotometry, Ultraviolet; Tablets; Technology, Pharmaceutical | 2006 |
Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Food, Fortified; Glucose Transporter Type 2; Glucosides; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Lansoprazole; Male; Oxidative Stress; Pancreas; PPAR gamma; Random Allocation; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2020 |